Tests ultrasound-guided radiofrequency ablation for solid pancreatic tumors
Tests a heat-based probe guided by endoscopic ultrasound to treat pancreatic tumors in adults.
Plain-language title generated from the registry record
Registry title: EUS-guided RFA for Pancreatic Neoplasms
Key facts
- Where
- Hong Kong, Hong KongSee the site
Where in Hong Kong
- Department of Surgery, Prince of Wales HospitalHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT03218345
- Record updated
- 20 March 2026
- Original description
Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms. The procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic neoplasms.Read full original descriptionShow less
Multi-center Prospective Study on EUS-guided Radiofrequency Ablation for Solid Pancreatic Neoplasms
Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms. The procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic neoplasms.
The aim of the current study is to perform a multi-center prospective study on EUS-guided radiofrequency ablation (RFA) of solid pancreatic neoplasms. The hypothesis is that EUS-guided RFA is safe, feasible and effective for treating solid pancreatic neoplasms.
Inclusion: Age 18 years-old or above; Suffering from pancreatic neuroendocrine tumor or pancreatic ductal carcinoma (<5cm in largest diameter) that was confirmed by fine needle aspiration cytology; Unsuitable for surgery, due to one (or more) of the following items:; ASA score > II*; An alternative advanced malignancy; Unsuitable for surgery upon expert's opinion for any other reason; Healthy individuals who are not keen for surgical resection; Eligible for endoscopic intervention; Written informed consent.
Exclusion: Patients with a poor mental condition or mental retardation, unable to understand the nature and possible consequences of the study; Patients with liver cirrhosis, portal hypertension and/or gastric varices; Coagulopathy (international normalized ratio >1.3, partial thromboplastin time greater than twice that of control), platelet count <50,000x103/uL; Pregnancy; Patients unwilling to undergo follow-up assessments.